COMPANY PROFILE

Glenmark Pharmaceuticals

Explore full profile

Research-driven, global, integrated pharmaceutical company headquartered at mumbai, india

Mumbai, IndiaFounded 1977Biotech & Life Sciences

Valuation $9.36B Market cap · 2026

Revenue $2.27B Latest reported FY

EBITDA $683M Latest reported FY

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a leading global biopharmaceutical company focused on discovering and developing innovative therapies to improve patient outcomes. Operating in over 50 countries, Glenmark serves a diverse range of clients including healthcare providers, hospitals, and pharmacies. The company specializes in generics, biosimilars, and novel drug discovery, targeting therapeutic areas such as cardiology, dermatology, and oncology. Glenmark's business model revolves around research and development (R&D) to create advanced medical solutions, which are then manufactured and distributed globally. Revenue is generated through the sale of these pharmaceutical products and licensing agreements. The company is recognized for its commitment to patient-centric initiatives and has received multiple awards for its contributions to healthcare.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1977
Headquarters: Mumbai, India
Listing: IPO 2000
Employees: 15,787
Open positions: 102
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Outside Tech
Client focus: b2b
Investment activity: 2 companies, latest Mar 2007
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	Aug 2018	—	—	True North Managers	—
IPO✓Exit	Nov 2003	$0	—	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$2.3B	+27.1%	$683M	30.1%	$185M	8.1%	$199M
2025	$1.8B	+13%	$335M	18.8%	$142M	8%	$199M
2024	$1.6B	-8.6%	$283M	17.9%	−$204M	-12.9%	$199M
2023	$1.7B	+4.5%	$352M	20.4%			$199M
2022	$1.7B	+12.7%	$339M	20.5%
2021	$1.5B	+3.9%	$290M	19.8%
2020	$1.4B	—	$252M	17.9%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Glenmark Pharmaceuticals website traffic

Latest recorded traffic for Glenmark Pharmaceuticals is 150K monthly website visits, down 51.6% over the last three months. Glenmark Pharmaceuticals's team grew 20.6% over the past year.

Latest monthly visits150K 3-month web change-51.6% 1-year team growth+20.6%

Monthly website visitsDec 2018–Oct 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

IPQA SpecialistMonroe, NC · Business Intelligence · Sep 6, 2026 Distribution Associate II, Inventory Control and SerializationAllentown, PA · Logistics · Sep 4, 2026 Senior Distribution ManagerMumbai, Maharashtra, India · Sales · Sep 4, 2026 General Manager Human Resources (Aurangabad)Aurangabad, Maharashtra, India · Human Resources · Sep 4, 2026 Sr. Manager- InvestigationsMumbai, Maharashtra, India · Other · Sep 3, 2026 Associate Director, LegalElmwood Park, NJ · Legal · Sep 1, 2026 Junior Accountant (Neuchâtel, Switzerland)Neuchâtel, Switzerland · Accounting · Sep 1, 2026 Group Product Manager / Senior Product Manager400001 Mumbai, India · Business Development · Aug 30, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
POpolypeptide.ltdPeptides Synthesis and Custom Manufacturers & factory Polypeptide.ltd	—	Operational	—	—	—
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
MPMindset PharmaPioneering next-generation psychedelic medicines for neurological and psychiatric disorders	Toronto, Canada	Acquired
MTMonument TherapeuticsPrecision neuroscience drugs for central nervous system diseases	Macclesfield, United Kingdom	Operational
ABArriVent BiopharmaAccelerating the Global Development of Innovative Biopharmaceutical Products	Upper Merion Township, United States	Operational
THThyreosThyreos Vaccines \| Bovine Respiratory Disease	Lincoln, United States	Operational
KPKashiv Specialty PharmaceuticalsAdvanced drug delivery and biosimilar platform for complex therapeutics. A subsidiary of Kashiv BioSciences acquired by Amneal	Bridgewater Township, United States	Acquired
BBBasking BiosciencesDeveloping a rapid-onset, short-acting thrombolytic drug for acute thrombosi	Raleigh, United States	Operational